Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06138002
Other study ID # CIV-23-05-043012
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date August 10, 2024

Study information

Verified date November 2023
Source Odix
Contact Valérie Gordenne
Phone +32476700214
Email valerie.gordenne@odixmedical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Low Back Pain (LBP) is one of the common causes of morbidity worldwide, with a one-month prevalence of 23.3 %. Number of people with LBP reached 577 million people in 2020. LBP has been the leading cause of years lived with disability from 1990 to 2017. The highest incidence of LBP is in people in their third decade of age. LBP is a complex disease difficult to treat as most of these cases (80 - 90 %) are classified as non-specific meaning that the pain cannot be attributed to any specific injury or pathology. Until now exercise therapy is commonly used as the treatment of choice in the revalidation program of LBP. The aim of physical treatment is to improve function and prevent disability from getting worse. LumbaCure® is a robotic system driven by a proprietary movement algorithm to induce a specific and controlled mobilization of the hips and the low back in patient requiring treatment by physical exercises due to orthopedic disorder, especially low back pain. The investigation include an intervention period of 4 weeks The main objective is to compare the impact on disability (Oswestry disability Index) and movement performance of the interventions (LumbaCure® vs physical exercises supervised by the physiotherapist) in two parallel groups of patients suffering from chronic low back pain. The investigation includes an intervention period of 4 weeks and a follow-up period of 6 months (post intervention period).


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 10, 2024
Est. primary completion date March 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Chronic non-specific LBP (without red flag) - Patient did not increase, on a long-term basis, his/her regular physical activity in the past 2 months. - LBP is the principal musculoskeletal condition - Aged between 18 and 65 years old - Able to read and understand questionnaires and communicate with the physiotherapist. - Average Back Pain intensity over the last week above 2, assessed on Numerical Pain Rating Scale from 0 to 10 anchored with "no pain" at 0 and "worst pain imaginable " at 10. - ODI score > 20 Exclusion Criteria: - Suspected or confirmed serious pathology (i.e infection, fracture, cancer, inflammatory arthritis, ….) - Radicular pain - Radiculopathy - Cognitive impairment that precludes participant from consenting, completing investigation questionnaires or complying with recommendations - Previous spine surgery in the last 3 months - Pregnant women - body weight > 120 kg - Neurological disease - Fibromyalgia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LumbaCure®
LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
Procedure:
Physical Exercises supervised by the physiotherapist
A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program

Locations

Country Name City State
Belgium Jessa Ziekenhuis vzw Hasselt
Belgium Jessa Ziekenhuis vzw Herk-de stad

Sponsors (1)

Lead Sponsor Collaborator
Odix

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient mobilization o Pressure distribution using a pressure mat LumbaCure® session 1 and session 12 : Week 1 (Day 0) and Week 4 (Day 25)
Other Measurement in Dynamic/static situation During standardized everyday dynamic/static movements (5x) : "sit-to-stand", 5 repetitions; climbing stairs", 5 repetitions; and "bending task", 30 sec position maintenance:
- Patient muscular activation of the back muscles is measured by surface EMG (sEMG). Targeted muscles: Iliocostalis, longissimus, multifidus, obliques.
Baseline and week 4 (end of intervention period)
Other Measurement in Dynamic/static situation During standardized everyday dynamic/static movements (5x) : "sit-to-stand", 5 repetitions; climbing stairs", 5 repetitions; and "bending task", 30 sec position maintenance:
- Patient Trunk acceleration, measured by IMU.
Baseline and week 4 (end of intervention period)
Other Flexion/extension amplitudes Flexion/extension amplitudes measured using the Tergumed or DavidBack device. Baseline and week 4 (end of intervention period)
Other Force Force measured using the Tergumed or DavidBack device. Baseline and week 4 (end of intervention period)
Other Distance finger to floor The ability of the patient to flex the lower back via fingertips to floor distance. Baseline and week 4 (end of intervention period)
Other Adverse events The occurrence, intensity and severity of adverse events will be monitored on both arm baseline, week 1, week 2, week 3, week 4
Primary Disability The change of the Oswestry Disability Index (ODI) between baseline and the end of the intervention period (4 weeks) Baseline, week 4 (end of intervention period)
Secondary Disability The change in the ODI score between baseline and follow-up period week2 (intervention period); month 1, month 3 and month 6 follow-up period
Secondary Disability responding rate Number and percentage of patients presenting an improvement from baseline of at least 10 points in the ODI week 2, week 4 (intervention period) and at month 1, month 3 and month 6 follow-up period
Secondary Back Pain Changes in the average back pain intensity over the last week from baseline, assessed on Numerical Pain Rating Scale from 0 to 10 (0 for no pain and 10 for worst pain imaginable) week 1, week 2, week 3 and week 4 (the intervention period)
Secondary Back Pain Changes in average back pain intensity over the last week from end of the intervention period (week 4), assessed on Numerical Rating Scale from 0 to 10 (0 for no pain and 10 for worst pain imaginable) in the follow-up period. month 1, month 3 and month 6 (follow-up period)
Secondary Back Pain responding rate Number and percentage of patients presenting an improvement from baseline of at least 1.5 points in the Numerical Pain rating scale week 2, week 4 (intervention period) and at month 1, month 3 and month 6 (follow-up period)
Secondary Function Change in function score from baseline, assessed using the Pain Specific Functional Scale. The PSFS requires participants to identify three problematic activities and to rate these activities on a scale from 0 to 10. week 4
Secondary Function Change in function score from the end of the intervention period (week 4) in the follow-up period, assessed using the Pain Specific Functional Scale. The PSFS requires participants to identify three problematic activities and to rate these activities on a scale from 0 to 10. Between end of intervention period and month 1, month 3 and 6 post-intervention
Secondary Function responding rate Number and percentage of patients presenting an improvement of at least 1.5 points from baseline in the pain specific function scale week 4 (intervention period) and at month 1, month 3 and month 6 (follow-up period)
Secondary Kinesiophobia Change in fear of movements and attitudes and behavior from baseline towards pain score, evaluated through the Tampa questionnaire. week 4
Secondary Kinesiophobia Change in fear of movements and attitudes and behavior from the end of intervention period (week4), towards pain score, evaluated through the Tampa questionnaire. month 1, month 3 and 6 (follow-up period)
Secondary Kinesiophobia responding rate Number and percentage of patients presenting an improvement of at least 6 points from baseline in Tampa scale. week 4 (intervention period) and month 1, month 3 and month 6 (follow-up period)
Secondary Anxiety and depression Change in Anxiety and depression score from baseline, assessed by the HAD questionnaire week 4
Secondary Anxiety and depression Change in Anxiety and depression score from end of the intervention period (week 4), assessed by the HAD questionnaire. month 1, month 3 and 6 (follow-up period)
Secondary Anxiety and depression responding rate Number and percentage of patients presenting an improvement of at least 2 points from baseline for each sub-scale anxiety and depression in the two treatment arms week 4 (intervention period) and month 1, month 3 and month 6 (follow-up period)
Secondary Physiotherapist global satisfaction A single score of satisfaction reported by the physiotherapist:
How satisfied or dissatisfied are you with the ability of the LumbaCure® intervention to improve your patient low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied); ?
How satisfied or dissatisfied are you with the ability of the Physical exercises intervention to improve your patient low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied)?
week 4
Secondary Patient global satisfaction of the therapy A single score of satisfaction will be calculated based on a set of two questions:
> How satisfied or dissatisfied are you with the ability of the LumbaCure® / Physical exercises intervention to improve your low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied)? How globally would you rate your experience, on the LumbaCure® device/with physical exercises (7-point Likert scale (1 = very bad; 7 = excellent)) ?
End of intervention period (week 4)
See also
  Status Clinical Trial Phase
Completed NCT03243084 - Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Completed NCT03162952 - RAND Center of Excellence for the Study of Appropriateness of Care in CAM
Completed NCT03240146 - Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain N/A
Completed NCT05282589 - Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients N/A
Completed NCT03637998 - Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain N/A
Recruiting NCT02289170 - Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) N/A
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT02231554 - Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial N/A
Recruiting NCT02063503 - Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT01704677 - Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up N/A
Completed NCT01177241 - Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids N/A
Completed NCT01490905 - A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain Phase 4
Completed NCT01177280 - Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes N/A
Completed NCT01177254 - Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions N/A
Completed NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Phase 3
Completed NCT00761150 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00763321 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00767806 - A Study for Patient With Chronic Low Back Pain Phase 3